Systemic Sclerosis With Pulmonary Involvement: Improving Diagnosis and Advances in Treatment
Upon successful completion of this activity, participants should be better able to:
- Evaluate the clinical symptomology and appropriate medical work-up for SSc to better identify patients in a timely manner and refer to a specialist, as warranted.
- Examine the burden of SSc on patient quality of life and the impact of pulmonary involvement on patient outcomes.
- Examine the latest clinical evidence regarding agents for the treatment of SSc, including the impact on skin score, lung function, and quality of life.
- Review the importance of multidisciplinary care for identifying patients with SSc and worsening pulmonary involvement who may benefit from emerging treatment options.
Click here to view this activity.
Systemic sclerosis (SSc) is a disabling autoimmune disorder that can cause diffuse fibrosis and vascular abnormalities in the skin, joints, and internal organs. Affecting approximately 2 million people worldwide, SSc is challenging to diagnose due to its nonspecific symptomatology and rare nature. Up to 90% of patients with SSc will have pulmonary involvement, and the presence of interstitial lung disease (ILD) is associated with poor prognosis. Currently, no disease-modifying therapies are available for treating SSc-ILD, but several agents approved for idiopathic pulmonary fibrosis are in late-stage clinical development. In this recorded symposium, experts review the presentation and workup of SSc, while addressing the burden of disease as well as evaluating the clinical evidence for current and emerging treatment options. Faculty also address the impact of SSc-ILD on patient prognosis and emphasize the importance of multidisciplinary care for timely identification of patients who may benefit from new treatments.
Activity Chair: Elana J. Bernstein, MD, MSc
Source: Healio Rheumatology Education Lab
Release Date: 3/17/2020
Expiration Date: 3/16/2021
Credit Type: CME
Number of Credits: 1.25
Provider: Vindico Medical Education
Provider Statement: This continuing medical education activity is provided by Vindico Medical Education.
Support Statement: This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Target Audience: The intended audience for the activity is rheumatologists and other health care professionals involved in the management of patients with systemic sclerosis.